VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...
Siren Biotechnology today announced the publication of its first peer-reviewed manuscript in Molecular Therapy Oncology, alongside upcoming presentations at the American Society of Gene and Cell ...
Avirmax Inc. will deliver two scientific presentations at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado May 3 - 7, 2026. ARVO is the largest ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...
Health and Me on MSN
US FDA approves 1st-ever gene therapy for treatment of genetic hearing loss
Developed by American Biotechnology company Regeneron, Otarmeni has been approved for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss. The ...
The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...
DUBLIN--(BUSINESS WIRE)--The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By ...
The viral vector specialist SIRION Biotech has announced the signing of a preferred partnership agreement with Heidelberg University Hospital ...
VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree AAV, a high-stability AAV vector designed to address ITR instability, a common challenge in ge ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results